(PubMed) Kim HJ, Chang WK, Kim MK, Lee SS, Choi BY
This multi-pronged approach may be especially beneficial for patients who have not achieved satisfactory results with single-agent therapies
Built for Research: Intended for laboratory research use only
No institutional review board has approved your individual use
A few commenters called for improvements in data transparency, including clearer and more timely preview reports, enhanced technical assistance, and access to simulation tools to help hospitals prepare for the 2027 methodology change
Highlights The first incretin hormone, gastric inhibitory peptide, was identified in the early 1970s, followed by the discovery of glucagonlike peptide 1 (GLP-1) in the 1980s [1]